[1]王小毛,黃 晶,石 峰.金龍膠囊對耐紫杉醇及卡鉑卵巢癌H08910細胞的逆轉及增敏作用[J].醫學信息,2020,(04):94-96.[doi:10.3969/j.issn.1006-1959.2020.04.028]
 WANG Xiao-mao,HUANG Jing,SHI Feng.Reversion and Sensitization Effect of Jinlong Capsule on Paclitaxel and Carboplatin-resistant Ovarian Cancer H08910 Cells[J].Medical Information,2020,(04):94-96.[doi:10.3969/j.issn.1006-1959.2020.04.028]
點擊復制

金龍膠囊對耐紫杉醇及卡鉑卵巢癌H08910細胞的逆轉及增敏作用()
分享到:

醫學信息[ISSN:1006-1959/CN:61-1278/R]

卷:
期數:
2020年04期
頁碼:
94-96
欄目:
論著
出版日期:
2020-02-15

文章信息/Info

Title:
Reversion and Sensitization Effect of Jinlong Capsule on Paclitaxel and Carboplatin-resistant Ovarian Cancer H08910 Cells
文章編號:
1006-1959(2020)04-0094-03
作者:
王小毛黃 晶石 峰
(1.贛州市腫瘤醫院藥劑科,江西 贛州 341000;2.贛州市腫瘤醫院婦瘤科,江西 贛州 341000;3.贛州市市立醫院藥劑科,江西 贛州 341000)
Author(s):
WANG Xiao-maoHUANG JingSHI Feng
(1.Department of Pharmacy,Ganzhou Cancer Hospital,Ganzhou 341000,Jiangxi,China;2.Department of Gynecology,Ganzhou Cancer Hospital,Ganzhou 341000,Jiangxi,China;3.Department of Pharmacy,Ganzhou Municipal Hospital,Ganzhou 341000,Jiangxi,China)
關鍵詞:
金龍膠囊紫杉醇卡鉑卵巢癌H08910細胞逆轉增敏
Keywords:
Jinlong capsulePaclitaxelCarboplatinOvarian cancer H08910 cellsReversalSensitization
分類號:
R737.31
DOI:
10.3969/j.issn.1006-1959.2020.04.028
文獻標志碼:
A
摘要:
目的 探討金龍膠囊在耐紫杉醇及卡鉑卵巢癌H08910細胞的逆轉作用及對H08910的致敏活性。方法 測定兩種耐藥細胞(卵巢癌H08910/Paclitaxel、卵巢癌H08910/Carboplatin)及相應親本卵巢癌H08910細胞的IC50,并將其與化療藥物組合的無毒濃度的金龍膠囊聯用,以XR9576(XR9576為P-gp抑制劑)為陽性對照藥,評估不同濃度(80、160、320 μg/ml)的金龍膠囊對耐紫杉醇的卵巢癌細胞、耐卡鉑的卵巢癌細胞及交叉耐藥的HO8910細胞的逆轉活性及增敏作用。結果 金龍膠囊在80、160、320 μg/ml無毒濃度對HO8910/Paclitaxel細胞對紫杉醇的耐藥RF倍數分別為1.89、2.48和4.08,但活性弱于陽性對照藥;金龍膠囊在80、160、320 μg/ml無毒濃度對HO8910/Paclitaxel細胞對卡鉑的交叉耐藥有逆轉作用。金龍膠囊在80、160、320 μg/ml無毒濃度對HO8910/Carboplatin細胞對紫杉醇的耐藥RF倍數分別為1.96、2.16和4.11,但活性弱于陽性對照藥;金龍膠囊在80、160、320 μg/ml無毒濃度對HO8910/Carboplatin細胞對卡鉑的交叉耐藥也有逆轉作用。金龍膠囊在80、160、320 μg/ml無毒濃度對HO8910細胞有增敏作用,對Paclitaxel及陽性對照藥表現一定量效關系。結論 金龍膠囊對聯合化療的耐藥細胞具有耐藥逆轉的作用,并且對化療藥物具有一定的增敏作用。
Abstract:
Objective To explore the reversal effect of Jinlong capsule on paclitaxel and carboplatin-resistant ovarian cancer H08910 cells and its sensitization activity to H08910.Methods The IC50 of two kinds of drug-resistant cells (ovarian cancer H08910/Paclitaxel, ovarian cancer H08910/Carboplatin) and corresponding parental ovarian cancer H08910 cells were measured, Combined with the non-toxic concentration of Jinlong capsules combined with chemotherapy drugs, XR9576 (XR9576 is a P-gp inhibitor) was used as a positive control drug, and Jinlong capsules of different concentrations (80,160,320 μg/ml) were evaluated. Reversal activity and sensitization of paclitaxel-resistant ovarian cancer cells, carboplatin-resistant ovarian cancer cells, and cross-resistant HO8910 cells.Results Jinlong capsules at 80, 160, and 320 μg/ml non-toxic concentrations of HO8910/Paclitaxel cells resistant to paclitaxel RF folds were 1.89, 2.48, and 4.08, respectively, but the activity was weaker than the positive control drug;Jinlong capsules at 80,160,320 μg/ml non-toxic concentrations can reverse the cross-resistance of HO8910/Paclitaxel cells to carboplatin. Jinlong capsules at 80,160,320 μg/ml non-toxic concentrations of HO8910/Carboplatin cells resistant to paclitaxel RF multiples of 1.96,2.16 and 4.11, respectively, but the activity is weaker than the positive control drug;Jinlong capsule also reversed the cross-resistance of HO8910/Carboplatin cells to carboplatin at non-toxic concentrations of 80, 160 and 320 μg/ml.Jinlong Capsules had a sensitizing effect on HO8910 cells at non-toxic concentrations of 80, 160 and 320 μg/ml, and showed a dose-effect relationship on Paclitaxel and positive control drugs.Conclusion Jinlong Capsule has the effect of reversing drug resistance of drug-resistant cells combined with chemotherapy, and has certain sensitizing effect on chemotherapy drugs.

參考文獻/References:

[1]楊欣影.α2,3唾液酸轉移酶Ⅲ調節卵巢癌細胞對紫杉醇敏感性的研究[D].暨南大學,2015. [2]曲育瑩,岳貴娟,李建生,等.金龍膠囊對耐紫杉醇及長春新堿腫瘤細胞株的逆轉及增敏作用[J].腫瘤防治研究,2014,41(8):884-887. [3]李丹,劉延慶.金龍膠囊抗腫瘤的研究進展[J].湖北中醫雜志,2018,40(8):59-62. [4]周慶斌,黃喜鋒,蔣鵬飛.金龍膠囊聯合化療對胃癌患者生活質量和免疫功能的影響[J].云南中醫學院學報,2017,40(6):26-29. [5]劉磊,胡春杰,李志杰,等.水飛薊賓誘導卵巢癌HO-8910細胞凋亡增殖及其機制探討[J].現代生物醫學進展,2017,17(20):3811-3815. [6]秦貞立,方英姬,黃曉戈.紫杉醇聯合卡鉑治療卵巢癌的效果分析[J].實用癌癥雜志,2015(2):286-287. [7]張曉前,南志宇.金龍膠囊聯合洛鉑對非小細胞肺癌肝轉移患者療效及免疫功能調節作用的觀察[J].中國藥物與臨床,2018,18(12):76-77. [8]李旭輝,惠雪楓,王艷梅,等.中藥單體逆轉腫瘤細胞多藥耐藥的作用機制[J].延安大學學報(醫學科學版),2019(2):96-99. [9]Shi J,Zhang W,He L,et al.Jinlong capsule inhibits migration and invasion in human glioblastoma cells via the modulation of mTOR/S6 signaling pathway[J].Drug Des Devel Ther,2019(13):1023-1032. [10]Zeng C,Cai L,Huang Z,et al.The effect of Jinlong capsule on the immune function for intervened patients with primary liver cancer[J].The Chinese-German Journal of Clinical Oncology,2014,13(2):80-83.

相似文獻/References:

[1]李思文,張 燕.不同紫杉醇劑型聯合卡鉑治療卵巢癌的療效研究[J].醫學信息,2019,(07):150.[doi:10.3969/j.issn.1006-1959.2019.07.046]
 LI Si-wen,ZHANG Yan.Therapeutic Effect of Different Paclitaxel Dosage Forms Combined With Carboplatin On Ovarian Cancer[J].Medical Information,2019,(04):150.[doi:10.3969/j.issn.1006-1959.2019.07.046]

更新日期/Last Update: 2020-02-15
中国足彩网竞彩 白银理财平台 七星彩论坛大公鸡 青海快3开奖号码今天71起 777娱乐电玩城游 上海11选五走势图一牛 大发快三有什么技巧吗 山东十一选五牛走势 江西多乐彩开奖 快乐双彩开奖结果彩吧助手 最近股市走势分析